PAK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL147331	0.91	2/20
SCHEMBL141930	0.90	2/20
SCHEMBL142206	0.85	2/20
SCHEMBL144842	0.80	2/20
SCHEMBL144192	0.75	2/20
SCHEMBL144525	0.71	2/20
SCHEMBL146263	0.71	2/20
SCHEMBL141676	0.69	2/20
SCHEMBL145500	0.69	2/20
SCHEMBL144281	0.68	2/20
SCHEMBL141372	0.68	2/20
SCHEMBL145902	0.67	2/20
SCHEMBL146743	0.67	2/20
SCHEMBL144785	0.67	2/20
SCHEMBL147096	0.63	2/20
SCHEMBL144209	0.62	2/20
SCHEMBL144321	0.61	2/20
SCHEMBL146728	0.61	2/20
SCHEMBL147975	0.60	2/20
SCHEMBL144930	0.60	2/20

Clinical trials — most relevant to PAK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas	PHASE1/PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome	PHASE1	COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Biomarker Analysis of Gastrointestinal Cancer	nan	UNKNOWN
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib	nan	COMPLETED
Tissue Bank of Biological Specimens From Patients With Gynecologic Disease	nan	UNKNOWN
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PAK3 binder may also engage these)

Protein	Name	Similarity
Q7YQL3	—	1.000	Q7YQL3 →
Q8AXB4	—	1.000	Q8AXB4 →
Q7YQL4	—	1.000	Q7YQL4 →
Q08E52	—	1.000	Q08E52 →
O88643	—	1.000	O88643 →
PAK2	Serine/threonine-protein kinase PAK 2	1.000	landscape →
Q17850	—	1.000	Q17850 →
PAK1	Serine/threonine-protein kinase PAK 1	1.000	landscape →
Q62829	—	1.000	Q62829 →
Q64303	—	1.000	Q64303 →
P35465	—	1.000	P35465 →
Q9NB31	—	0.998	Q9NB31 →
A4K2M3	—	0.997	A4K2M3 →
Q61036	—	0.997	Q61036 →
Q8CIN4	—	0.996	Q8CIN4 →
A4K2Y1	—	0.996	A4K2Y1 →
DCLK1	Serine/threonine-protein kinase DCLK1	0.996	landscape →
Q9JI10	—	0.996	Q9JI10 →
Q5E9L6	—	0.995	Q5E9L6 →
Q4KSH7	—	0.995	Q4KSH7 →
Q2VWQ3	—	0.995	Q2VWQ3 →
Q802A6	—	0.994	Q802A6 →
STK24	Serine/threonine-protein kinase 24	0.994	landscape →
Q9HFW2	—	0.994	Q9HFW2 →
O61125	—	0.994	O61125 →
STK4	Serine/threonine-protein kinase 4	0.994	landscape →
P36582	—	0.994	P36582 →
Q9JLM8	—	0.994	Q9JLM8 →
A4K2Q5	—	0.994	A4K2Q5 →
Q05512	—	0.993	Q05512 →